Vanessa Research, Inc. is proud to announce the incorporation of its Hungarian subsidiary, Vanessa Research Hungary, Ltd. The Budapest based unit is a key milestone in the company’s strategic plan to manufacture and distribute its flagship product, Shylicine™, that eliminates the need for Total Parental Nutrition (TPN) in the treatment of the lethal rare disease called Microvillus Inclusion Disease (MVID).
“The Hungarian presence opens new horizons for the company. In collaborations with the National Competent Authority, we have a great chance to accelerate the European launch of our flagship product Shylicine™, said Benjamin Szabo, J.D. the company’s secretary.
The new subsidiary will also serve to advance the business “incubator” mentality by forming collaborations with Hungarian and other Central European Innovation Centers with the hope of opening markets to both European and US entrepreneurs.
“The excellent geographic location and EU membership of Hungary, combined with the supportive atmosphere will allow us to expand our business opportunities in Europe. We are optimistic that our approach and extensive business network in the United States will greatly facilitate innovation in a Hungarian-receptive environment”, Szabo went on to explain.
The company expects the Budapest unit to become a central player in its plan for organic growth.
For more information, please contact: info@vanessaresearch.com